Sarcopenic obesity: from the onset to interventions
Authors:
Tereza Vágnerová 1,2; Martin Šaier 3
Authors‘ workplace:
Geriatrická klinika 1. LF UK a VFN, Praha
1; Ústav hygieny a epidemiologie 1. LF UK a VFN, Praha
2; III. interní klinika – endokrinologie a metabolismu 1. LF UK a VFN, Praha
3
Published in:
Geriatrie a Gerontologie 2021, 10, č. 1: 23-30
Category:
Review Article
Overview
Vágnerová T, Šaier M. Sarcopenic obesity: from the onset to interventions
Sarcopenic obesity is a specific type of obesity, a medical condition defined as the coexistence of low muscle strength and mass and increased adipose tissue. In obesity, skeletal and visceral muscle infiltration with adipose tissue (myosteatosis) occurs, which negatively affects functional capacity and, secondarily, self-sufficiency and the overall quality of life of the elderly person. The main role in the development of SO plays a chronic proinflammatory state with increased production of inflammatory cytokines and hormones secreted by adipose tissue. The presence of sarcopenia and SO respectively, is most often diagnosed by imaging techniques (DXA, CT, MRI). In clinical practice bioimpedance analysis of body composition seems useful and physical functions are evaluated using comprehensive performance tests. SO is associated with serious negative health outcomes and with socio-economic consequences: increase in morbidity, mortality, contribution to cardiovascular diseases, type 2 diabetes mellitus, prolonged hospital stay, slower wound healing, and impaired cognitive function. Nevertheless, SO also represents important modifiable risk factor, where changes of lifestyle play a crucial role in prevention and treatment. The aerobic and strength training combined with the nutritionist guided caloric restriction with sufficient protein intake appears to be the most effective interventions.
Keywords:
sarcopenia – sarcopenic obesity –movement intervention – nutritional intervention
Sources
1. Prado CMM, Wells JCK, Smith SR, et al. Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr 2012; 31(5): 583–601.
2. Batsis JA, Mackenzie TA, Barre LK, et al. Sarcopenia, sarcopenic obesity and mortality in older adults: results from the National Health and Nutrition Examination Survey III. Eur J Clin Nutr 2014; 68(9): 1001–1007.
3. Sakuma K, Yamaguchi A. Sarcopenic obesity and endocrinal adaptation with age. Int J Endocrinol online 2013; 2013: 204164.
4. Morgan PT, Smeuninx B, Breen L. Exploring the impact of obesity on skeletal muscle function in older age. Front Nutr 2020; 7: 569904.
5. Prokopidis K, Cervo MM, Gandham A, Scott D. Impact of protein intake in older adults with sarcopenia and obesity: a gut microbiota perspective. Nutrients 2020; 12(8): 2285.
6. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018; 14(9): 513–537.
7. Bouchonville MF, Villareal DT. Sarcopenic obesity: how do we treat it? Curr Opin Endocrinol Diabetes Obes 2013; 20(5): 412–419.
8. Petroni ML, Caletti MT, Dalle Grave R, et al. Prevention and treatment of sarcopenic obesity in women. Nutrients 2019; 11(6): 1302.
9. Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev 2017; 35: 200–221.
10. 2021 ICD-10-CM Diagnosis Codes E65-68. Dostupné na: https://www.icd10data.com/ICD10CM/Codes/E00-E89/E65-E68
11. 2021 ICD-10-CM Diagnosis Code M62.84. Dostupné na: http://www.icd10data.com/ICD10CM/Codes/M00-M99/M60-M63/M62-/M62.84
12. Vellas B, Fielding RA, Bens C, et al. Implications of ICD-10 for sarcopenia clinical practice and clinical trials: report by the International Conference on Frailty and Sarcopenia Research Task Force. J Frailty Aging 2018; 7(1): 2–9.
13. Roh E, Choi KM. Health consequences of sarcopenic obesity: a narrative review. Front Endocrinol 2020; 11: 332.
14. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised european consensus on definition and diagnosis. Age Ageing 2019; 48(1): 16–31.
15. Cruz-Jentoft AJ, Baeyens J-P, Bauer JM, et al. Sarcopenia: european consensus on definition and diagnosis. Age Ageing 2010; 39(4): 412–423.
16. von Berens Å, Obling SR, Nydahl M, et al. Sarcopenic obesity and associations with mortality in older women and men – a prospective observational study. BMC Geriatr 2020; 20(1): 199.
17. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization Technical Report Series 2000; 894: i–xii/1–253.
18. Jarolimova J, Tagoni J, Stern TA. Obesity: its epidemiology, comorbidities, and management. Prim Care Companion CNS Disord 2013; 15(5): PCC.12f01475.
19. Winter JE, Macinnis RJ, Wattanapenpaiboon N, Nowson CA. BMI and all-cause mortality in older adults: a meta-analysis. Am J Clin Nutr 2014; 99(4): 875–890.
20. Alberti KGMM, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366(9491): 1059–1062.
21. Batsis JA, Mackenzie TA, Lopez-Jimenez F, Bartels SJ. Sarcopenia, sarcopenic obesity and functional impairments in older adults: NHANES 1999–2004. Nutr Res 2015; 35(12): 1031–1039.
22. Hwang B, Lim J-Y, Lee J, et al. Prevalence rate and associated factors of sarcopenic obesity in korean elderly population. J Korean Med Sci 2012; 27(7): 748–755.
23. Donini LM, Busetto L, Bauer JM, et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clin Nutr 2020; 39(8): 2368–2388.
24. Volkert D, Beck AM, Cederholm T, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nut 2019; 38(1): 10–47.
25. Keller K, Engelhardt M. Strength and muscle mass loss with aging process. Age and strength loss. Muscles Ligaments Tendons J 2014; 3(4): 346–350.
26. Sayer AA, Syddall H, Martin H, et al. The developmental origins of sarcopenia. J Nutr Health Aging 2008; 12(7): 427–432.
27. Mourtzakis M, Prado CMM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33(5): 997–1006.
28. Polyzos SA; Margioris AN. Sarcopenic obesity. Hormones 2018; 17(3): 321–331.
29. Poggiogalle E, Parrinello E, Barazzoni R, et al. Therapeutic strategies for sarcopenic obesity: a systematic review. Curr Opin Clin Nutr Metab Care 2021; 24(1): 33–41.
30. Kim TN, Park MS, Lim KI, et al. Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol 2013; 78(4): 525–532.
31. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 2006; 116(1): 33–35.
32. Batsis JA, Mackenzie TA, Jones JD, et al. Sarcopenia, sarcopenic obesity and inflammation: results from the 1999–2004 National Health and Nutrition Examination Survey. Clin Nutr 2016; 35(6): 1472–1483.
33. da Cunha Nascimento D, da Cunha Oliveira S, Vieira DCL, et al. The impact of sarcopenic obesity on inflammation, lean body mass, and muscle strength in elderly women. Int J Gen Med 2018; 11: 443–449.
34. Schrager MA, Metter EJ, Simonsick E, et al. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol 2007; 102(3): 919–925.
35. Lim JP, Leung BP, Ding YY, et al. Monocyte chemoattractant protein-1: a proinflammatory cytokine elevated in sarcopenic obesity. Clin Interv Aging 2015; 10: 605–609.
36. Shimabukuro M. Leptin Resistance and lipolysis of white adipose tissue: an implication to ectopic fat disposition and its consequences. J Atheroscler Thromb 2017; 24(11): 1088–1089.
37. Wannamethee SG, Atkins JL. Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc 2015; 74(4): 405–412.
38. Meng S-J, Yu L-J. Oxidative stress, molecular inflammation and sarcopenia. Int J Mol Sci 2010; 11(4): 1509–1526.
39. Chen L, Chen R, Wang H, Liang F. Mechanisms linking inflammation to insulin resistance. Int J Endocrinol 2015; 2015: 508409.
40. Abbatecola AM, Ferrucci L, Ceda G, et al. Insulin resistance and muscle strength in older persons. J Gerontol Series A 2005; 60(10): 1278–1282.
41. Kob R, Bollheimer LC, Bertsch T, et al. Sarcopenic obesity: molecular clues to a better understanding of its pathogenesis? Biogerontology 2015; 16(1): 15–29.
42. Abbatecola AM, Paolisso G, Fattoretti P, et al. Discovering pathways of sarcopenia in older adults: a role for insulin resistance on mitochondria dysfunction. J Nutr Health Aging 2011; 15(10): 890–895.
43. Collins-Hooper H, Sartori R, Macharia R, et al. Propeptide-mediated inhibition of myostatin increases muscle mass through inhibiting proteolytic pathways in aged mice. J Gerontol Series A 2014; 69(9): 1049–1059.
44. Camporez J-PG, Petersen M, Abudukadier A, et al. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice. Proc Natl Acad Sci USA 2016; 113(8): 2212–2217.
45. Murphy KT, Koopman R, Naim T, et al. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J 2010; 24(11): 4433–4442.
46. Chang JS, Kim TH, Nguyen TT, et al. Circulating irisin levels as a predictive biomarker for sarcopenia: a cross-sectional community-based study. Geriatr Gerontol Int 2017; 17(11): 2266–2273.
47. Colaianni G, Cinti S, Colucci S, Grano M. Irisin and musculoskeletal health. Ann NY Acad Sci 2017; 1402(1): 5–9.
48. Wang C, Bai L. Sarcopenia in the elderly: basic and clinical issues. Geriatr Gerontol Int 2012; 12(3): 388–396.
49. Sipilä S, Narici M, Kjaer M, et al. Sex hormones and skeletal muscle weakness. Biogerontology 2013; 14(3): 231–245.
50. Choi KM. Sarcopenia and sarcopenic obesity. Korean J Intern Med 2016; 31(6): 1054–1060.
51. Liu P, Hao Q, Hai S, et al. Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: a systematic review and meta-analysis. Maturitas 2017; 103: 16–22.
52. Tian S, Xu Y. Association of sarcopenic obesity with the risk of all-cause mortality: a meta-analysis of prospective cohort studies. Geriatr Gerontol Int 2016; 16(2): 155–166.
53. Sanada K, Chen R, Willcox B, et al. Association of sarcopenic obesity predicted by anthropometric measurements and 24-y all-cause mortality in elderly men: the Kuakini Honolulu Heart Program. Nutrition 2018; 46: 97–102.
54. Hong, S-H, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. Int J Mol Sci 2020; 21(2): 494
55. Khadra D, Itani L, Tannir H, et al. Association between sarcopenic obesity and higher risk of type 2 diabetes in adults: A systematic review and meta-analysis. World J Diabetes 2019; 10(5): 311–323.
56. Carneiro IP, Mazurak VC, Prado CM. Clinical implications of sarcopenic obesity in cancer. Curr Oncol Rep 2016; 18(10): 62.
57. Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol 2018; 29(Suppl 2): ii1–ii9.
58. Tolea MI, Chrisphonte S, Galvin JE. Sarcopenic obesity and cognitive performance. Clin Interv Aging 2018; 13: 1111–1119.
59. Öztürk ZA, Türkbeyler İH, Abiyev A, et al. Health-related quality of life and fall risk associated with age-related body composition changes; sarcopenia, obesity and sarcopenic obesity. Intern Med J 2018; 48(8): 973–981.
60. Prado CM, Anker SD, Coats AJS, et al. Nutrition in the spotlight in cachexia, sarcopenia and muscle: avoiding the wildfire. J Cachexia Sarcopen Muscle 2000, December 31. doi: https://doi.org/10.1002/jcsm.12673
61. Koliaki Ch, Liatis S, Dalamaga M, Kokkinos A. Sarcopenic obesity: epidemiologic evidence, pathophysiology, and therapeutic perspectives. Curr Obes Rep 2019; 8(4): 458–471.
62. Garber CE, Blissmer B, Deschenes MR, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011; 43(7): 1334–1359.
63. Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. New Engl J Med 2017; 376(20): 1943–1955.
64. Burton E, Farrier K, Lewin G, et al. Motivators and barriers for older people participating in resistance training: a systematic review, J Aging Phys Act 2017; 25(2): 311–324.
65. O’Brien MW, Robinson SA, Frayne R, et al. Achieving Canadian physical activity guidelines is associated with better vascular function independent of aerobic fitness and sedentary time in older adults. Appl Physiol Nutr Metab 2018; 43(10): 1003–1009.
66. Forbes SC, Candow DG, Ferreira LHB, Souza-Junior TP. Effects of creatine supplementation on properties of muscle, bone, and brain function in older adults: a narrative review. J Dietary Suppl 2021, January 27. Dostupné na: https://www.tandfonline.com/doi/abs/10.1080/19390211.2021.1877232
67. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Direct Assoc 2013; 14(8): 542–559.
68. Gielen E, Beckwée D, Delaere A, et al. Nutritional interventions to improve muscle mass, muscle strength, and physical performance in older people: an umbrella review of systematic reviews and meta-analyses. Nutr Rev 2021; 79(2): 121–147.
Labels
Geriatrics General practitioner for adults Orthopaedic prostheticsArticle was published in
Geriatrics and Gerontology
2021 Issue 1
Most read in this issue
- Sarcopenic obesity: from the onset to interventions
-
Nutritional guidelines in geriatrics
The nutrition care process and screening -
The assessment of disability using WHODAS 2.0 tool at geriatric patients.
A pilot study WHODAS-GERI - Mobility as a key factor for healthy ageing